News from REMEDY

The network for decentralized studies in HSØ launches new websites and invites to its first seminar, Monday 25 November. The seminar requires registration.

The authors Jens Vikse, Espen A. Haavardsholm and Øyvind Molberg presented the book and all the cooperation with the rheumatology community behind it.

Several researchers from the REMEDY Center contributed insightful presentations during the 13th National Musculoskeletal Health Research Conference (MUSS) 2024

A REMEDY-led international panel has developed new guidelines based on the best available research, where studies from REMEDY (NOR-DRUM) are a central part of the knowledge base. The underlying question: Can proactive TDM improve treatment outcomes for adults with inflammatory bowel disease, inflammatory arthritis, or psoriasis using biologics compared to standard care?

Kristine Røren Nordén has researched how personalized, high-intensity training can improve aerobic capacity in these patients. 

Diseases that form part of the specialty of rheumatology are often referred to as rheumatic diseases or rheumatological diseases. Among the rheumatologists, there are divided opinions about which of these expressions is preferred, and it is the subject of the language column in the journal 25/10/24

The hospital is in the process of completing a state-of-the-art biobank facility at Vinderen. The premises must ensure safe storage of valuable biological material. This is important for the hospital's long-term investment in research and personalized medicine. The facilities will be ready by the end of 2024.

Minister of Health Jan Christian Vestre visited Diakonhjemmet hospital on 15 October. He wants to ensure that the apps in work package 5 do not have to be CE-marked as high-risk medical equipment.

All About Clinical Trials course will be held at Diakonhjemmet hospital, Oslo 12-13. December 2024. It is a generic course that covers all aspects of clinical trials. Although built by cardiologists, it is relevant to anyone interested in clinical trials. The course is particularly suitable for PhD candidates.